Selumetinib Terminated Phase 2 Trials for Stage IIIc Melanoma / Stage IIIA Melanoma / Recurrent Melanoma / Stage IIIB Melanoma / Stage IV Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01519427Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib